A Double-Blind, Randomized, Placebo-Controlled, Ascending Single-Dose, Phase I Trial of the Anti-Orthopoxvirus Compound SIGA-246 in Healthy Volunteers.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Ascending Single-Dose, Phase I Trial of the Anti-Orthopoxvirus Compound SIGA-246 in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Tecovirimat (Primary)
  • Indications Orthopoxvirus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 13 Apr 2008 Results presented at International Conference on Antiviral Research in April 2008.
    • 02 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top